23andMe, one of the world’s largest biotech companies, is now facing bankruptcy, raising concerns about the security of its vast genetic data.

Founded in 2006, the company gained popularity with its affordable DNA testing kits, used by millions to learn about their health and ancestry.

Despite initial success and going public in 2021, 23andMe’s financial struggles have escalated.

With 14 million users to date, privacy concerns loom over the future of customers’ personal genetic data, Science Alert has reported.

The company, along with competitors like AncestryDNA and MyHeritage, dominates a $3 billion direct-to-consumer genetic testing market.

Written by B.C. Begley